Since FVB/N mice that lack Cdkn2a are cancer-prone, primarily developing leukemia/lymphoma and sarcoma, we transplanted BM of THS-exposed and control Cdkn2a null mice into histocompatible BM-ablated recipient animals. This evidence concerns the gene CDKN2A and sarcoma.